The Organic Chemistry of Drug Design and Drug Action, Third Edition, represents a unique approach to medicinal chemistry based on physical organic chemical principles and reaction mechanisms that rationalize drug action, which allows the reader to extrapolate those core principles and mechanisms to many related classes of drug molecules. This new edition reflects significant changes in the process of drug design over the last decade. It preserves the successful approach of the previous editions while including significant changes in format and coverage.
New to this edition:
Updates to all chapters, including new examples and referencesChapter 1 (Introduction): Completely rewritten and expanded as an overview of topics discussed in detail throughout the bookChapter 2 (Lead Discovery and Lead Modification): Sections on sources of compounds for screening including library collections, virtual screening, and computational methods, as well as hit-to-lead and scaffold hopping; expanded sections on sources of lead compounds, fragment-based lead discovery, and molecular graphics; and deemphasized solid-phase synthesis and combinatorial chemistryChapter 3 (Receptors): Drug-receptor interactions, cation-p and halogen bonding; atropisomers; case history of the insomnia drug suvorexantChapter 4 (Enzymes): Expanded sections on enzyme catalysis in drug discovery and enzyme synthesisChapter 5 (Enzyme Inhibition and Inactivation): New case histories: for competitive inhibition, the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib and Abelson kinase inhibitor, imatinibfor transition state analogue inhibition, the purine nucleoside phosphorylase inhibitors, forodesine and DADMe-ImmH, as well as the mechanism of the multisubstrate analog inhibitor isoniazidfor slow, tight-binding inhibition, the dipeptidyl peptidase-4 inhibitor, saxagliptinChapter 7 (Drug Resistance and Drug Synergism): This new chapter includes topics taken from two chapters in the previous edition, with many new examplesChapter 8 (Drug Metabolism): Discussions of toxicophores and reactive metabolitesChapter 9 (Prodrugs and Drug Delivery Systems): Discussion of antibody-drug conjugates
Table of contents :
Content:
Front Matter, Page iii
Copyright, Page iv
Dedications, Page v
Preface to the First Edition, Page xiii
Preface to the Second Edition, Pages xv-xvi
Preface to the Third Edition, Pages xvii-xviii
Chapter 1 - Introduction, Pages 1-17
Chapter 2 - Lead Discovery and Lead Modification, Pages 19-122
Chapter 3 - Receptors, Pages 123-163
Chapter 4 - Enzymes, Pages 165-205
Chapter 5 - Enzyme Inhibition and Inactivation, Pages 207-274
Chapter 6 - DNA-Interactive Agents, Pages 275-331
Chapter 7 - Drug Resistance and Drug Synergism, Pages 333-356
Chapter 8 - Drug Metabolism, Pages 357-422
Chapter 9 - Prodrugs and Drug Delivery Systems, Pages 423-468
Appendix - Answers to Chapter Problems, Pages 469-506
Index, Pages 507-517